URGN – urogen pharma ltd. - ordinary shares (US:NASDAQ)
Stock Stats
News
UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024
UroGen Pharma Ltd. (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $54.00 price target on the stock.
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers [Yahoo! Finance]
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer [Yahoo! Finance]
Form 10-K/A UroGen Pharma Ltd. For: Dec 31
Form 4 UroGen Pharma Ltd. For: Mar 18 Filed by: Schoenberg Mark
Form 144 UroGen Pharma Ltd. Filed by: Schoenberg Mark
Form 10-K UroGen Pharma Ltd. For: Dec 31
Form 8-K UroGen Pharma Ltd. For: Mar 14
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.